Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes

被引:108
作者
Asakura, Keiichi [1 ,2 ,3 ,4 ,5 ]
Hayashi, Seiji [1 ,2 ,5 ]
Ojima, Atsuko [2 ,6 ]
Taniguchi, Tomohiko [2 ,3 ,4 ,6 ]
Miyamoto, Norimasa [2 ,3 ,4 ,6 ]
Nakamori, Chiaki [4 ,7 ]
Nagasawa, Chiho [4 ,7 ]
Kitamura, Tetsuo [4 ,8 ]
Osada, Tomoharu [1 ,2 ,8 ]
Honda, Yayoi [4 ,9 ]
Kasai, Chieko [1 ,2 ,10 ]
Ando, Hiroyuki [1 ,2 ,4 ,11 ]
Kanda, Yasunari [1 ,2 ,12 ]
Sekino, Yuko [1 ,2 ,12 ]
Sawada, Kohei [1 ,2 ,6 ]
机构
[1] JSPS, Maebashi, Gunma 3718511, Japan
[2] JiCSA, Setagaya Ku, Tokyo 1588501, Japan
[3] JPMA, Nonclin Evaluat Expert Comm, Drug Evaluat Comm, Chuo Ku, Tokyo 1030023, Japan
[4] Consortium Safety Assessment Using Human IPS Cell, Tokyo, Japan
[5] Nippon Shinyaku Co Ltd, Minami Ku, Kyoto 6018550, Japan
[6] Eisai & Co Ltd, Tsukuba, Ibaraki 3002635, Japan
[7] Taisho Pharmaceut Co Ltd, Kita Ku, Saitama, Saitama 3319530, Japan
[8] LSI Medience Corp, Chiyoda Ku, Tokyo 1018517, Japan
[9] Sumitomo Dainippon Pharma Co Ltd, Konohana Ku, Osaka 5540022, Japan
[10] Astellas Pharma Inc, Yodogawa Ku, Osaka 5328514, Japan
[11] Ono Pharmaceut Co Ltd, Fukui 9138538, Japan
[12] NIHS, Setagaya Ku, Tokyo 1588501, Japan
关键词
Action potential; Field potential; High-pass filter; Human induced pluripotent stem cell-derived cardiomyocytes; Membrane potential dye; Multi-electrode array; QT INTERVAL; SAFETY PHARMACOLOGY; PRECLINICAL SAFETY; ACTION-POTENTIALS; REPOLARIZATION; ASSAYS; TECHNOLOGIES; ARRHYTHMIAS; MULTISITE; DRUGS;
D O I
10.1016/j.vascn.2015.04.002
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Introduction: Multi-electrode array (MEA) systems and human induced pluripotent stem (iPS) cell-derived cardiomyocytes are frequently used to characterize the electrophysiological effects of drug candidates for the prediction of QT prolongation and proarrhythmic potential. However, the optimal experimental conditions for obtaining reliable experimental data, such as high-pass filter (HPF) frequency and cell plating density, remain to be determined. Methods: Extracellular field potentials (FPs) were recorded from iPS cell-derived cardiomyocyte sheets by using the MED64 and MEA2100 multi-electrode array systems. Effects of HPF frequency (0.1 or 1 Hz) on FP duration (FPD) were assessed in the presence and absence of moxifloxacin, terfenadine, and aspirin. The influence of cell density on FP characteristics recorded through a 0.1-Hz HPF was examined. The relationship between FP and action potential (AP) was elucidated by simultaneous recording of FP and AP using a membrane potential dye. Results: Many of the FP waveforms recorded through a 1-Hz HPF were markedly deformed and appeared differentiated compared with those recorded through a 0.1-Hz HPF. The concentration-response curves for FPD in the presence of terfenadine reached a steady state at concentrations of 0.1 and 0.3 mu M when a 0.1-Hz HPF was used. In contrast, FPD decreased at a concentration of 0.3 mu Mwith a characteristic bell-shaped concentration-response curve when a 1-Hz HPF was used. The amplitude of the first and second peaks in the FP waveform increased with increasing cell plating density. The second peak of the FP waveform roughly coincided with AP signal at 50% re-polarization, and the negative deflection at the second peak of the FP waveform in the presence of E-4031 corresponded to early afterdepolarization and triggered activity. Discussion: FP can be used to assess the QT prolongation and proarrhythmic potential of drug candidates; however, experimental conditions such as HPF frequency are important for obtaining reliable data. (C) 2015 The Authors. Published by Elsevier Inc.
引用
收藏
页码:17 / 26
页数:10
相关论文
共 31 条
[2]
Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative [J].
Cavero, Icilio ;
Holzgrefe, Henry .
EXPERT OPINION ON DRUG SAFETY, 2014, 13 (06) :745-758
[3]
Egert U, 2005, PRACTICAL METHODS IN CARDIOVASCULAR RESEARCH, P432, DOI 10.1007/3-540-26574-0_22
[4]
Egert U., 2006, ADV NETW ELECTROPHYS, V22, P274
[5]
Fejtl M., 2006, ADV NETWORK ELECTROP, P24, DOI [DOI 10.1007/0-387-25858-2_2, 10.1007/0-387-25858-2_2]
[6]
Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents [J].
Gibson, John K. ;
Yue, Yimei ;
Bronson, Jared ;
Palmer, Cassie ;
Numann, Randy .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2014, 70 (03) :255-267
[7]
An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation [J].
Gintant, Gary .
PHARMACOLOGY & THERAPEUTICS, 2011, 129 (02) :109-119
[8]
Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures [J].
Halbach, MD ;
Egert, U ;
Hescheler, J ;
Banach, K .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2003, 13 (05) :271-284
[9]
Comparison of Electrophysiological Data From Human-Induced Pluripotent Stem CellDerived Cardiomyocytes to Functional Preclinical Safety Assays [J].
Harris, Kate ;
Aylott, Mike ;
Cui, Yi ;
Louttit, James B. ;
McMahon, Nicholas C. ;
Sridhar, Arun .
TOXICOLOGICAL SCIENCES, 2013, 134 (02) :412-426
[10]
Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology [J].
Hayakawa, Tomohiro ;
Kunihiro, Takeshi ;
Ando, Tomoko ;
Kobayashi, Seiji ;
Matsui, Eriko ;
Yada, Hiroaki ;
Kanda, Yasunari ;
Kurokawa, Junko ;
Furukawa, Tetsushi .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2014, 77 :178-191